Mcewen Mng Inc SEC Filings

Ian J. Ball, a director of McEwen Inc. (MUX), reported the sale of 2,656 shares of the issuer's common stock on 08/12/2025. The filing reports the shares were sold (transaction code S) at a weighted average price of $10.49 per share, based on Canadian dollar sale prices of C$14.44–C$14.45 converted at C$1.00 = US$0.7260. Following the reported transaction, the form shows 0 shares beneficially owned by the reporting person in a Canadian RRSP account (indirect ownership). The Form 4 is signed by the reporting person on 08/14/2025.

Stephan Michael Spears, reporting as an officer of McEwen Inc. (MUX), disclosed equity awards granted on 08/11/2025. The filing shows an acquisition of 40,000 stock options with an exercise price of $10.43 and 3,600 restricted stock units (RSUs), both reported as direct ownership. The option award vests in three equal annual installments beginning August 11, 2026. Each RSU represents a contingent right to one share or cash and will vest in three installments on Dec 29, 2025, Jun 29, 2026 and Dec 29, 2026.

The filing is an individual Form 4 for the issuer McEwen Inc. (ticker MUX) with the earliest transaction date stated as 08/11/2025 and the form signed on 08/13/2025. The report identifies Spears as an officer with the title VP Corporate Development. No dispositions, cash payments, or other transactions are reported in this filing.

Richard W. Brissenden, a director of McEwen Inc. (MUX), was granted a stock option that gives him the right to purchase up to 20,000 common shares at an exercise price of $10.43 per share. The option was recorded with an effective transaction date of 08/11/2025 and shows an expiration date of 08/11/2030. The grant vests in three equal annual installments beginning 08/11/2026, and the shares underlying the option are reported as directly owned by the reporting person following the transaction.

This Form 4 discloses the specific terms of the derivative award (exercise price, number of shares, vesting schedule and expiration) but does not provide information on total insider holdings relative to outstanding shares or any cash payments made in connection with the grant.

McEwen Inc. General Counsel Carmen L. Diges reported acquisitions of equity awards tied to the issuer's common stock. On 08/11/2025 she acquired 40,000 stock options with an exercise price of $10.43 and 3,900 restricted stock units. The option award is subject to a vesting schedule that begins on August 11, 2026 and vests in three equal annual installments. Each restricted stock unit represents a contingent right to one share or cash and vests in three equal installments on December 29, 2025, June 29, 2026 and December 29, 2026.

The reporting form shows these holdings as direct beneficial ownership. The filings identify Ms. Diges as an officer serving as General Counsel and Corporate Secretary and list the number of securities beneficially owned following the transactions as 40,000 options and 3,900 RSUs.

McEwen Inc. director Michael Nelson Melanson was granted 10,000 stock options on 08/11/2025 with an exercise (conversion) price of $10.43. The filing reports these options as directly beneficially owned by Mr. Melanson following the grant and shows no cash purchase associated with the grant.

The options vest in three equal annual installments beginning August 11, 2026 and expire on August 11, 2030. The filing is a single-person Form 4 reporting this equity award to a company director; it contains no other transactions, cash exercises, or changes in outstanding common stock reported.

McEwen Inc. director Dalia Nadine Asterbadi was granted a stock option for 10,000 shares of common stock with a $10.43 exercise price on 08/11/2025. The option vests in three equal annual installments beginning 08/11/2026 and is exercisable through 08/11/2030, and the reporting person is shown as the direct beneficial owner of 10,000 options following the transaction.

This grant ties a board member’s compensation to the company’s share performance and creates potential future dilution if the options are exercised, while the staged vesting supports retention over the next three years.

William M. Shaver, who serves as Chief Operating Officer and a director of McEwen Inc. (MUX), was granted equity awards on 08/11/2025 consisting of a stock option and restricted stock units. The stock option gives the right to buy 80,000 shares at an exercise price of $10.43, vests in three equal annual installments beginning August 11, 2026, is exercisable through August 11, 2030, and is held directly. The restricted stock units total 6,300, represent the contingent right to one share (or cash at the issuer's discretion), and vest in three installments on December 29, 2025, June 29, 2026 and December 29, 2026.

The reported transactions are grants (acquisitions) rather than dispositions. Following the awards the filing shows beneficial ownership of 80,000 option interests and 6,300 RSUs held directly by Mr. Shaver. The disclosure is a routine insider compensation event providing equity linkage between management and common stock performance.

John Casimir Florek, a director of McEwen Inc. (MUX), was granted 10,000 stock options with an exercise price of $10.43. The transaction is recorded with an effective date of 08/11/2025. The options are classified as a stock option (right to buy) and are held directly by Mr. Florek following the reported transaction.

The award vests in three equal annual installments beginning 08/11/2026 and expires on 08/11/2030. In practical terms, the grant ties part of a director's potential compensation to the company's share price, while the staggered vesting delays any immediate exercise; full realization would require exercise at or above the $10.43 strike and would introduce up to 10,000 additional shares on exercise.

McEwen Inc. director Nicolas Darveau-Garneau was granted 20,000 stock options on 08/11/2025 with an exercise price of $10.43. The options give the right to buy common stock and are reported as held directly.

The grant vests in three equal annual installments beginning 08/11/2026 and includes an apparent expiration date of 08/11/2030. The filing lists the acquisition of 20,000 derivative securities (stock options) under the Form 4 disclosure.